Why Dendreon (DNDN) Stock Is Surging Today

NEW YORK (TheStreet) -- Dendreon  (DNDN) surged Tuesday after the company announced data from ProACT and IMPACT studies on PROVENGE, or sipuleucel-T.

The data indicated PROVENGE treatment induced an antigen spread associated with an overall survival benefit in cases of advanced prostate cancer. The company also announced data from the PROCEED registry that indicated similar treatment patterns for urologists and oncologists in PROVENGE-treated patients with metastatic castration-resistant prostate cancer (mCRPC).

The company plans to present the ProACT and IMPACT data via a podium presentation at the 2014 American Urological Association from May 16 to May 21 in Orlando. Dendreon will present the PROCEED data in a general poster session.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 8.41% to $2.32 at 10:49 a.m.

DNDN Chart

DNDN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

This Will Be the Ultimate Buy (or Sell) Signal for Stocks

This Will Be the Ultimate Buy (or Sell) Signal for Stocks

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Here's What Wall Street Is Watching Monday as Stocks Nosedive

Here's What Wall Street Is Watching Monday as Stocks Nosedive

Dow Falls Sharply, Nasdaq Sinks as Wall Street Weighs Trump's New Trade Threats

Dow Falls Sharply, Nasdaq Sinks as Wall Street Weighs Trump's New Trade Threats

Jim Cramer: Reports of Attempted Trade Truce With China Are False

Jim Cramer: Reports of Attempted Trade Truce With China Are False